Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 2:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
indacaterol and glycopyrronium (QVA149), glycopyrronium (NVA237), indacaterol (QAB149), tiotropium, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
2,144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Fullerton, California • Riverside, California • St. Petersburg, Florida + 11 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tofimilast
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
23
States / cities
Phoenix, Arizona • Riverside, California • Clearwater, Florida + 18 more
Completed Not applicable Interventional Accepts healthy volunteers

Translating The GOLD COPD Guidelines Into Primary Care Practice

NCT01237561
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
provider support tools plus spirometer
Other
Lead sponsor
Memorial Hospital of Rhode Island
Other
Eligibility
40 Years to 80 Years
Enrollment
3,593 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Pawtucket, Rhode Island
Active, not recruiting No phase listed Observational Accepts healthy volunteers

High Resolution Micro OCT Imaging

NCT03256773
Conditions
Cystic Fibrosis, COPD, PCD - Primary Ciliary Dyskinesia, Covid19, Sinusitis, ILD, Normal Controls
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Completed No phase listed Observational Results available

Alpha-1 Carrier Genomics Study

NCT02810327
Conditions
Alpha-1 Antitrypsin Deficiency, Emphysema, COPD, Smoking
Interventions
Genetic Sequencing
Genetic
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab Arm A, Benralizumab Arm B, Benralizumab Arm C, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
2,255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
151
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Montgomery, Alabama + 127 more
Active, not recruiting Not applicable Interventional

Transitional Care Model Evaluation 2020

NCT04212962
Conditions
CHF - Congestive Heart Failure, COPD, Pneumonia
Interventions
Transitional care model (TCM), Usual care
Behavioral
Lead sponsor
Mathematica Policy Research, Inc.
Other
Eligibility
65 Years and older
Enrollment
962 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Princeton, New Jersey
Enrolling by invitation Phase 2 Interventional

Chronic Exogenous Ketosis in HFpEF

NCT06937320
Conditions
Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Normal Ejection Fraction, Heart Failure, Diastolic
Interventions
Exogenous Ketone Drink, Placebo
Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
COPD
Interventions
Telehealth Program
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
45 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Kansas City, Kansas
Not yet recruiting Phase 1Phase 2 Interventional

Brain State-dependent PCMS in Chronic Stroke

NCT04830163
Conditions
Stroke
Interventions
Brain state-dependent paired corticomotoneuronal stimulation (PCMS)
Combination Product
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Austin, Texas
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Not listed
Lead sponsor
LASARRUS Clinic and Research Center
Industry
Eligibility
21 Years to 100 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Salisbury, Maryland
Conditions
cGVHD
Interventions
Non-Interventional
Other
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more
Conditions
COPD
Interventions
BGF MDI 320/14.4/9.6 μg, GFF MDI (PT003) 14.4/9.6 μg, BFF MDI (PT009) 320/9.6 μg, Symbicort® Turbuhaler® (TBH) Inhalation Powder
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
63
States / cities
Andalusia, Alabama • Jasper, Alabama • Peoria, Arizona + 54 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Propionate/Salmeterol Combination Product, Salmeterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
95
States / cities
Jasper, Alabama • Mobile, Alabama • Glendale, Arizona + 88 more
Not listed Not applicable Interventional Accepts healthy volunteers

Airvo 3 Respiratory Rate Validation Study

NCT06329609
Conditions
COPD, Healthy Volunteers
Interventions
Airvo 3 with respiratory rate algorithm
Device
Lead sponsor
Fisher and Paykel Healthcare
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Louisville, Colorado
Completed Not applicable Interventional Results available

IVR-Enhanced Care Transition Support for Complex Patients

NCT01135381
Conditions
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Interventions
IVR-Enhanced Care
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Lung Disease, Chronic Obstructive, Lung Disease, Interstitial
Interventions
Not listed
Lead sponsor
Echosense Ltd.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Obstructive Sleep Apnea, OSA COPD Overlap Syndrome
Interventions
Positive airway pressure, NIPPV and /or oxygen
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years to 89 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Asthma, Pulmonary Disease, Chronic Obstructive
Interventions
Medical tests
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
9
States / cities
Birmingham, Alabama • New Haven, Connecticut • Chicago, Illinois + 6 more
Recruiting Not applicable Interventional

MoblO2 to Maintain Oxygenation

NCT07704567
Conditions
COPD (Chronic Obstructive Pulmonary Disease), Intersitital Lung Disease
Interventions
MoblO2 controls O2 flow, MoblO2 does not control flow
Other
Lead sponsor
Minnesota HealthSolutions
Industry
Eligibility
25 Years to 95 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Denver, Colorado
Terminated Not applicable Interventional Results available

Nasal High Flow Therapy 30 Day Readmission Study

NCT02552732
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
NHF with or without Oxygen
Device
Lead sponsor
Fisher and Paykel Healthcare
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Liverpool, New York
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
NJOY e-cigarette
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 74 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
Interventions
Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID, Formoterol 12 ųg BID, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
60
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 56 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone propionate/salmeterol inhalation powder DISKUS 250/50, tiotropium bromide inhalation powder HandiHaler
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Torrance, California + 15 more